Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot
May 02 2023 - 7:59AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
MetasiteTM, today announced its partnership with the Digital
Medicine Society (DiMe) in support of the CancerX inaugural
project. Answering the call of the White House, Science 37 will
join DiMe and Moffitt Cancer Center as part of CancerX, a new
public-private partnership effort to rapidly accelerate the pace of
cancer innovation in the U.S., alongside the Office for the
National Coordinator for Health Information Technology (ONC) and
Office of the Assistant Secretary for Health (OASH).
CancerX was recently announced by U.S. President Joe Biden and
Dr. Jill Biden as part of the reignited national Cancer Moonshot
initiative. It will unite the diverse stakeholders and innovators
necessary to unleash the power of innovation to design and create a
future that's free of the burden of cancer.
Through this partnership, Science 37 will work with the CancerX
project team and participating clinical trial sponsors on the
inaugural project, “Advancing Digital Innovation to Improve Equity
and Reduce Financial Toxicity in Cancer Care and Research.” This
project will further advance remote conduct in oncology trials,
including precision medicine, early cancer detection, and long-term
follow-up for cell and gene therapy.
“Science 37’s virtual site, the Metasite, is already leading the
way to enable access and equity in clinical trials,” said Dr.
Shaalan Beg, VP of Oncology at Science 37. “From breast cancer
studies requiring at-home administration of anticancer treatment
every three weeks that significantly reduced patient burden, to
early detection cancer studies where we’ve enrolled more than 24%
minority representation with 25,000+ medical records collected; the
pace of progress in oncology research that our Metasite enables is
unparalleled. Our team brings unique expertise in implementing
virtual research tools by engaging patients and oncology practices.
We are delighted to support the White House CancerX and Cancer
Moonshot initiative to further enable equity in oncology
research.”
“We are thrilled to partner with Science 37 on the inaugural
project for CancerX to use digital innovation to improve equity and
reduce financial toxicity in cancer care and research,” said Sarah
Sheehan, DiMe Oncology Program Lead. "Today, cancer is the second
leading cause of death in the United States and those with a cancer
diagnosis are much more likely to experience an adverse financial
event than those without. Our work will unleash the power of
digital innovation to democratize access to better quality health
and economic outcomes after cancer treatment for a broader
coalition of patients."
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to accelerate clinical research by
enabling universal trial access for patients. Through our Metasite™
we reach an expanded population beyond the traditional site,
delivering on our goal of clinical research that works for
everyone—with greater patient diversity. Patients gain the
flexibility to participate from the comfort of their own homes, at
their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the products offered by Science 37 and the
markets in which it operates, and Science 37’s anticipated growth
and profitability. These forward-looking statements generally are
identified by the words “believe,” “can,” “could”, “seek”,
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022 filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023 and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From May 2023 to May 2024